Results 71 to 80 of about 380,300 (294)

Large‐scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation

FEBS Open Bio, EarlyView.
Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane, Lea Nikolić, Lorenzo Maraio, Thomas Goiran, Nathan Karpilovsky, Stefano Sellitto, Vangelis Bouris, Jiang‐An Yin, Ronald Melki, Edward A Fon, Adriano Aguzzi, Elena De Cecco   +11 more
wiley   +1 more source

Ecstasy and neurodegeneration [PDF]

BMJ, 1996
Publicity in the popular press and medical journals1 on the dangers of using ecstasy (3,4-methylenedioxymethamphetamine) has concentrated almost exclusively on the problems of acute toxicity. While the unnecessary death of any young person is rightly deplored, it is strange that so little attention is being paid to the long term effects of this ...
A R, Green, G M, Goodwin
openaire   +2 more sources

Intercompartmental communication in senescence

FEBS Open Bio, EarlyView.
Senescent cells experience structural changes in the plasma membrane, endoplasmic reticulum, mitochondria, lysosomes, nucleus, and cytoskeleton. These alterations disrupt crosstalk among cellular compartments, impairing vesicular trafficking, contact sites, and molecular flow.
Krystyna Mazan‐Mamczarz, Eleanor J. Wind, Jixiang Leng, Myriam Gorospe   +3 more
wiley   +1 more source

Glycation of alpha-synuclein enhances aggregation and neuroinflammatory responses

npj Parkinson's Disease
The risk of developing Parkinson’s disease (PD) is elevated in individuals with type 2 diabetes (T2DM), but the molecular pathways underlying this link remain unclear.
Eftychia Vasili, Annekatrin König, Mohammed Al-Azzani, Clara Bosbach, Luisa Maria Gatzemeier, Searlait Thom, Ana Chegão, Hugo Vicente Miranda, Claudia Steinem, Daniel Erskine, Tiago F. Outeiro   +10 more
doaj   +1 more source

Longitudinal change in ATN biomarkers in cognitively normal individuals

Alzheimer’s Research & Therapy, 2022
Background Biomarkers for amyloid, tau, and neurodegeneration (ATN) have predictive value for clinical progression, but it is not clear how individuals move through these stages.
Jarith L. Ebenau, Denise Visser, Lior A. Kroeze, Mardou S. S. A. van Leeuwenstijn, Argonde C. van Harten, Albert D. Windhorst, Sandeep V. S. Golla, Ronald Boellaard, Philip Scheltens, Frederik Barkhof, Bart N. M. van Berckel, Wiesje M. van der Flier   +11 more
doaj   +1 more source

Reformulating Pro-Oxidant Microglia in Neurodegeneration [PDF]

, 2019
In neurodegenerative diseases, microglia-mediated neuroinflammation and oxidative stress are central events. Recent genome-wide transcriptomic analyses of microglial cells under different disease conditions have uncovered a new subpopulation named ...
Alonso Bellido, Isabel María, Burguillos García, Miguel Ángel, Cruz Hernández, Luis, Espinosa Oliva, Ana María, García Domínguez, Irene, García Revilla, Juan, Herrera Carmona, Antonio José, Martínez de Pablos, Rocío, Roca Ceballos, María Angustias, Rodríguez Gómez, José Antonio, Ruiz Laza, Rocío, Santiago Pavón, Martiniano, Sarmiento Soto, Manuel, Venero Recio, José Luis   +13 more
core   +2 more sources

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammation

Molecular Neurodegeneration
Background LRRK2-targeting therapeutics that inhibit LRRK2 kinase activity have advanced to clinical trials in idiopathic Parkinson’s disease (iPD). LRRK2 phosphorylates Rab10 on endolysosomes in phagocytic cells to promote some types of immunological ...
Yuan Yuan, Huizhong Li, Kashyap Sreeram, Tuyana Malankhanova, Ravindra Boddu, Samuel Strader, Allison Chang, Nicole Bryant, Talene A. Yacoubian, David G. Standaert, Madalynn Erb, Darren J. Moore, Laurie H. Sanders, Michael W. Lutz, Dmitry Velmeshev, Andrew B. West   +15 more
doaj   +1 more source

Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia. [PDF]

, 2014
An inherited deficiency of the mitochondrial protein frataxin causes Friedreich's ataxia (FRDA); the mechanism by which this deficiency triggers neuro- and cardio-degeneration is unclear.
Cortopassi, Gino, Hayashi, Genki, Newman, John W, Pedersen, Theresa L, Pook, Mark, Shen, Yan   +5 more
core   +1 more source

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky, Cara Joyce, H. Jeremy Bockholt, Paul A. Rudnick, William H. Adams, Fiona McAllister, Justin W. Smock, Michael A. Newton, Jane S. Paulsen   +8 more
wiley   +1 more source